Matthew Wikler Net Worth

Matthew Wikler biography

Dr. Matthew A. Wikler M.D. serves as Independent Director of the Company. Dr. has served as a member of our board of directors since January 2018. Dr. Wikler currently serves as the Principal of Infectious Disease Technology Development Consulting (IDTD Consulting) where he provides clinical, medical and regulatory strategic insight to companies developing new technologies for the treatment and prevention of infectious diseases, a position he has held since 2015. Prior to that from 2012 to 2015, Dr. Wikler served at The Medicines Company (NASDAQ: MDCO) as VP, New Business Ventures and VP and Medical Director, Infectious Disease Care. Over the course of his career Dr. Wikler held senior leaderships positions for a number of pharmaceutical companies, including as Chief Development Officer of Rib-X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections, President and Chief Executive Officer of IASO Pharma Inc., a privately-held clinical stage biotechnology company focused on the development of antibacterial and antifungal therapeutics, the Institute for One World Health, a 501(c)(3) nonprofit drug development organization, Dr. Wikler earned a B.A. in Chemistry from Franklin and Marshall, an M.D. degree from Temple University School of Medicine, and his M.B.A. from the University Of Pennsylvania Wharton School Of Business. He completed his Infectious Diseases Fellowship at the Hospital of the University of Pennsylvania and is a Fellow of the Infectious Diseases Society of America.

How old is Matthew Wikler?

Matthew Wikler is 70, he's been the Independent Director of Matinas Biopharma Inc since 2018. There are 3 older and 13 younger executives at Matinas Biopharma Inc. The oldest executive at Matinas Biopharma Holdings Inc is Herbert Conrad, 87, who is the Independent Chairman of the Board.

What's Matthew Wikler's mailing address?

Matthew's mailing address filed with the SEC is C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER,, NJ, 07921.

Insiders trading at Matinas Biopharma Inc

Over the last 8 years, insiders at Matinas Biopharma Inc have traded over $0 worth of Matinas Biopharma Inc stock and bought 1,157,037 units worth $1,139,222 . The most active insiders traders include Patrick G Lepore, Adam K Stern und James S Scibetta. On average, Matinas Biopharma Inc executives and independent directors trade stock every 40 days with the average trade being worth of $187,938. The most recent stock trade was executed by Adam K Stern on 21 August 2020, trading 20,000 units of MTNB stock currently worth $16,600.

What does Matinas Biopharma Inc do?

matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec

Matinas Biopharma Inc executives and stock owners

Matinas Biopharma Inc executives and other stock owners filed with the SEC include:

• Jerome Jabbour,
  President, Chief Executive Officer, Director
• Keith Kucinski,
  Chief Financial Officer
• James Ferguson,
  Chief Medical Officer
• Jerome D. Jabbour J.D.,
  Co-Founder, CEO, Pres & Director
• Theresa Matkovits,
  Chief Development Officer
• Dr. James J. Ferguson FACC, M.D.,
  Chief Medical Officer
• Dr. Theresa Matkovits Ph.D.,
  Chief Devel. Officer
• Raphael Mannino,
  Chief Scientific Officer
• Ian Cooney,
  Director ,Investor Relations & Corporate Development
• Matthew Wikler,
  Independent Director
• James Scibetta,
  Independent Director
• Natasha Giordano,
  Independent Director
• Eric Ende,
  Independent Director
• Patrick LePore,
  Independent Vice Chairman of the board
• Herbert Conrad,
  Independent Chairman of the Board
• Thomas J. Hoover M.B.A.,
  Chief Bus. Officer
• Frank Calamusa,
  Exec. Director and Head of Manufacturing & Supply Chain
• Dr. Raphael J. Mannino Ph.D.,
  Chief Scientific Officer
• Dr. Hui Liu M.B.A., Ph.D.,
  Chief Technology Officer
• Keith A. Kucinski CPA, M.B.A.,
  Chief Financial Officer
• Adam K Stern,
  Director
• Dominick Di Paolo,
  Senior VP of Compliance
• Gary Gaglione,
  Chief Financial Officer
• Roelof Rongen,
  Chief Executive Officer
• Jennifer Gjg Life Sciences,...,
  
• Stefano Ferrari,
  Director
• Hui Liu,
  Chief Technology Officer
• Kathryn Penkus Corzo,
  Director
• Thomas Hoover,
  Chief Business Officer